LON:SCLP

Scancell Share Forecast, Price & News

GBX 21
+0.10 (+0.48 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
21
21.45
50-Day Range
19
24
52-Week Range
4.96
29
Volume493,849 shs
Average Volume2.05 million shs
Market Capitalization£171.20 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SCLP News and Ratings via Email

Sign-up to receive the latest news and ratings for Scancell and its competitors with MarketBeat's FREE daily newsletter.


Scancell logo

About Scancell

Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors. The company has a research collaboration agreement with BioNTech to develop T-cell receptor based therapeutics; licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the development and commercialization of Modi-1; and collaboration agreements with Cobra Biologics, Centre for Research on Global Virus Infections, the University of Nottingham, and the Nottingham Trent University to develop a vaccine for COVID-19. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Headlines

Scancell Hlds : Director Dealing
Scancell Hlds : Director Dealing
June 13, 2021 |  markets.businessinsider.com
Scancell Hlds : Price Monitoring Extension
Scancell Hlds : Price Monitoring Extension
June 13, 2021 |  markets.businessinsider.com
I’d buy this Covid-19-related penny stock
I’d buy this Covid-19-related penny stock
March 17, 2021 |  fool.co.uk
Scancell Hlds - Price Monitoring Extension
Scancell Hlds - Price Monitoring Extension
December 20, 2020 |  proactiveinvestors.com
Scancell Holdings Regulatory News
Scancell Holdings Regulatory News
October 15, 2020 |  lse.co.uk
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Scancell (LON:SCLP) Frequently Asked Questions

What stocks does MarketBeat like better than Scancell?

Wall Street analysts have given Scancell a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Scancell wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Scancell's earnings last quarter?

Scancell Holdings plc (LON:SCLP) announced its quarterly earnings data on Friday, January, 31st. The company reported ($0.56) earnings per share for the quarter.
View Scancell's earnings history
.

How has Scancell's stock price been impacted by Coronavirus?

Scancell's stock was trading at GBX 5.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SCLP shares have increased by 259.0% and is now trading at GBX 21.
View which stocks have been most impacted by COVID-19
.

Who are Scancell's key executives?

Scancell's management team includes the following people:
  • Dr. Clifford Holloway, CEO & Director
  • Prof. Lindy Gillian Durrant, Chief Scientific Officer & Director
  • Dr. Sally Elizabeth Adams, Chief Devel. Officer & Director (Age 60, Pay $213.72k)
  • Mr. Keith Green, Director of Fin. & Admin.
  • Dr. Samantha Paston, Head of Research
  • Dr. Adrian Parry, Head of Manufacturing
  • Dr. Gillies O'Bryan-Tear, Chief Medical Officer
  • Ms. Akua Asare, Head of Quality

Who are some of Scancell's key competitors?

What other stocks do shareholders of Scancell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scancell investors own include KAZ Minerals (KAZ), Standard Chartered (STAN), Petropavlovsk (POG), AorTech International (AOR), Ascential (ASCL), Advanced Oncotherapy (AVO), Empyrean Energy (EME), Lloyds Banking Group (LYG), Aminex (AEX) and Sound Energy (SOU).

What is Scancell's stock symbol?

Scancell trades on the London Stock Exchange (LON) under the ticker symbol "SCLP."

How do I buy shares of Scancell?

Shares of SCLP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Scancell's stock price today?

One share of SCLP stock can currently be purchased for approximately GBX 21.

How much money does Scancell make?

Scancell has a market capitalization of £171.20 million.

How many employees does Scancell have?

Scancell employs 22 workers across the globe.

What is Scancell's official website?

The official website for Scancell is www.scancell.co.uk.

Where are Scancell's headquarters?

Scancell is headquartered at Department of Clinical Oncology Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom.

How can I contact Scancell?

Scancell's mailing address is Department of Clinical Oncology Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The company can be reached via phone at +44-115-8231863.


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.